By Steven Reinberg
Since 2012, the cost of antiviral treatment for HIV, the virus that causes AIDS, has jumped 34%. That's nearly four times the inflation rate.
Even with new generic options, initial treatments now top $36,000 per patient per year, according to the study.
In 2012, the average annual cost of initial treatment was $25,000 to $35,000. By 2018, the range was $36,000 to $48,000 a year, researchers found. That's a 53% increase, nearly six times the inflation rate.
"Clearly, there is a movement by the industry to increase drug prices, and there's been advertising to try and make sure that people who might be on older, cheaper drugs transition to newer, more expensive ones," said lead researcher Dr. Rochelle Walensky, a professor of medicine at Harvard Medical School in Boston.
Walensky noted that the federal government's "Ending the HIV Epidemic" initiative aims to see a 90% reduction in new HIV cases by 2030.
To meet that goal, the United States needs to increase viral suppression by 33%. That will require spending nearly $36 billion a year on medicine alone, she said.
"In many cases, it's really the public paying for these drugs," she said.
One reason prices are climbing is that deep pools of government and private money -- including expanded Medicaid and the Ryan White HIV/AIDS Program -- cover these drugs. Another reason: There is no government oversight to control prices, Walensky said.
"The public needs to keep an eye on these drug costs because they're rising rapidly," Walensky said. "That's unacceptable, and we are in the midst of a public health mission to end this epidemic, and we're not going to be able to do it if these costs continue to increase at these rates."
Andrew Powaleny -- spokesman for PhRMA, the trade group representing the pharmaceutical industry -- said breakthroughs in HIV drugs have significantly reduced deaths from the disease. "These innovations are meaningless, however, if patients can't afford them," he added.
While not addressing why prices have risen so dramatically, Powaleny mentioned some industry efforts to make HIV drugs more affordable to patients.
Those efforts include discounts and rebates that the new research does not take into account, he said. Powaleny said the industry is trying to make sure those savings are shared with patients at the pharmacy counter.
"Biopharmaceutical companies are working to fix the health care system so it works better for patients by improving patient affordability," he said.
The industry also would like to see a cap on out-of-pocket costs and coinsurance lowered from 25% to 20%, Powaleny said.
"We also need to delink supply chain payments from the list price of a medicine," he said.
The report was published online Feb. 3 as a research letter in JAMA Internal Medicine.